371157-17-4

Basic information

• Product Name: 5-(3,4-DIMETHOXYPHENYL)-3-ISOXAZOLECARBOXYLIC ACID ETHYL ESTER
• Synonyms: 5-(3, 4-DIMETHOXYPHENYL)-ISOXAZOLE-3-CARBOXYLIC ACID ETHYL ESTER;5-(3,4-DIMETHOXYPHENYL)-3-ISOXAZOLECARBOXYLIC ACID ETHYL ESTER
• CAS NO: 371157-17-4
• Molecular Formula: C14H15NO5
• Molecular Weight: 0
• Mol File: 371157-17-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-(3,4-DIMETHOXYPHENYL)-3-ISOXAZOLECARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(3,4-DIMETHOXYPHENYL)-3-ISOXAZOLECARBOXYLIC ACID ETHYL ESTER(371157-17-4)
• EPA Substance Registry System: 5-(3,4-DIMETHOXYPHENYL)-3-ISOXAZOLECARBOXYLIC ACID ETHYL ESTER(371157-17-4)

Safety Data

• Hazardous Substances Data: 371157-17-4(Hazardous Substances Data)

Upstream product

• 14337-43-0 ethyl 2-chloro-2-(hydroxyimino)acetate 
• 70909-46-5 ethyl 4-(3,4-dimethoxyphenyl)-2,4-dioxobutanoate 
• 1131-62-0 1-(3,4-dimethoxyphenyl)ethanone 

Relevant articles and documents

Novel N-benzylpiperidine derivatives of 5-arylisoxazole-3-carboxamides as anti-Alzheimer's agents

The complex pathophysiology of Alzheimer's disease (AD) has prompted researchers to develop multitarget-directed molecules to find an effective therapy against the disease. In this context, a novel series of N-(1-benzylpiperidin-4-yl)-5-arylisoxazole-3-ca

Design and synthesis of novel 5-arylisoxazole-1,3,4-thiadiazole hybrids as α-glucosidase inhibitors

Background: α-Glucosidase inhibitors have occupied a significant position in the treatment of type 2 diabetes. In this respect, the development of novel and efficient non-sugar-based inhibitors is in high demand. Objective: Design and synthesis of new 5-arylisoxazole-1,3,4-thiadiazole hybrids possessing α-glucosidase inhibitory activity were developed. Methods: Different derivatives were synthesized by the reaction of various 5-arylisoxazole-3-carboxylic acids and ethyl 2-((5-amino-1,3,4-thiadiazol-2-yl)thio)acetate. Finally, they were evalu-ated for their α-glucosidase inhibitory activity. Results: It was found that ethyl 2-((5-(5-(2-chlorophenyl)isoxazole-3-carboxamido)-1,3,4-thiadiazol-2-yl)thio)acetate (5j) was the most potent compound (IC50 = 180.1 μM) compared with acarbose as the reference drug (IC50 = 750.0 μM). Also, the kinetic study of 5j revealed a competitive inhibition and docking study results indicated desired interactions of that compound with amino acid residues located close to the active site of α-glucosidase. Conclusion: Good α-glucosidase inhibitory activity obtained by the title compounds introduced them as an efficient scaffold, which merits to be considered in anti-diabetic drug discovery developments.

Development of a continuous flow photoisomerization reaction converting isoxazoles into diverse oxazole products

A continuous flow process is presented, which directly converts isoxazoles into their oxazole counterparts via a photochemical transposition reaction. This results in the first reported exploitation of this transformation to establish its scope and synthe

Design and Synthesis of Novel Arylisoxazole-Chromenone Carboxamides: Investigation of Biological Activities Associated with Alzheimer's Disease

A novel series of hybrid arylisoxazole-chromenone carboxamides were designed, synthesized, and evaluated for their cholinesterase (ChE) inhibitory activity based on the modified Ellman's method. Among synthesized compounds, 5-(3-nitrophenyl)-N-{4-[(2-oxo-

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

Novel hybrid molecules of isoxazole chalcone derivatives: Synthesis and study of In Vitro cytotoxic activities

Background: Now-a-days, the model of “hybrid drugs” has acquired recognition in medicine due to their significant role in the treatment of different health problems. Methods: We have synthesized new series of isoxazole-chalcone conjugates (14a-m) by the C

1,2,3-Triazole-isoxazole based acetylcholinesterase inhibitors: Synthesis, biological evaluation and docking study

In this work, a series of derivatives containing 1,2,3-triazole and isoxazole were synthesized. All of them were evaluated as novel dual AChE inhibitors. Most of synthesized compounds showed moderate to good inhibitory potency toward AChE. Among them, N-(

Novel indole-isoxazole hybrids: Synthesis and in vitro anti-cholinesterase activity

Background: This work reports synthesis and in vitro cholinesterase inhibitory activity of novel indole-isoxazole hybrids. Method: The synthetic procedure was started from different ethyl 5-Arylisoxazole-3-carboxylate derivatives. Hydrolysis and reaction

Synthesis and in Vitro Cytotoxic Activity of Novel Triazole-Isoxazole Derivatives

New derivatives of triazole-isoxazole were synthesized through a four-step reaction starting from various ethyl 4-aryl-2,4-dioxobutanoate derivatives. Finally, all compounds were examined by MTT assays for cytotoxic activity in two human breast cancer cell lines (MCF-7 and T-47D).

2-Amino-3-cyano-4-(5-arylisoxazol-3-yl)-4H-chromenes: Synthesis and in vitro cytotoxic activity

A new series of 4-aryl-4H-chromenes bearing a 5-arylisoxazol-3-yl moiety at the C-4 position were prepared as potential anticancer agents. The in vitro cytotoxic activity of the synthesized compounds was investigated against a panel of tumor cell lines in